Sebastian Sendel

Dr. Sebastian Sendel

HMU - Health and Medical University Campus Erfurt, Germany, Erfurt, Thuringia, Germany
+1
orcid
né Koch

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Genes
Verified
Journal Article
Open access
PDF file
Sebastian SendelSebastian Sendel
Sebastian Sendel
BLBjörn-Hergen Laabs
Björn-Hergen Laabs
MKMeike Kasten
Meike Kasten
EVEva-Juliane Vollstedt
Eva-Juliane Vollstedt
JBJos Becktepe
Jos Becktepe
ACAmke Caliebe
Amke Caliebe
Idiopathic Parkinson’s disease (PD) is a complex multifactorial disorder caused by the interplay of both genetic and non-genetic risk factors. Polygenic risk scores (PRSs) are one way to aggregate the effects of a large number of genetic variants upon the risk for a disease like PD in a single quantity. However, reassessment of the performance of a given PRS in independent data sets is a precondition for establishing the PRS as a valid tool to this end. We studied a previously proposed PRS for PD in a separate genetic data set, comprising 1914 PD cases and 4464 controls, and were able to replicate its ability to differentiate between cases and controls. We also assessed theoretically the prognostic value of the PD-PRS, i.e., its ability to predict the development of PD in later life for healthy individuals. As it turned out, the PD-PRS alone can be expected to perform poorly in this regard. Therefore, we conclude that the PD-PRS could serve as an important research tool, but that meaningful PRS-based prognosis of PD at an individual level is not feasible.

24 February 2026 in Annals of Neurology
Verified
Journal Article
Open access
TLTheresa Lüth
Theresa Lüth
BLBjörn‐Hergen Laabs
Björn‐Hergen Laabs
Sebastian SendelSebastian Sendel
Sebastian Sendel
IKInke R. König
Inke R. König
ACAmke Caliebe
Amke Caliebe
JTJoanne Trinh
Joanne Trinh
Objectives: The objective of this study was to elucidate differences in the cumulative incidence of Leucine‐rich repeat kinase 2 (LRRK2) p.Gly2019Ser ‐ related Parkinson's disease (PD; LRRK2 ‐PD) between ancestries and countries. Methods: We included 922 unrelated p.Gly2019Ser variant carriers (affected = 762 and unaffected = 160) from the Global Parkinson's Genetics Program (GP2) in addition to cohorts recruited from the Israeli Ashkenazi Jewish and Tunisian Arab‐Berber population. Cox proportional hazard models were applied to examine differences in cumulative incidence across ancestry groups and countries. All analyses were adjusted for biological sex and were exploratory. Results: The median age at onset (AAO) of LRRK2 ‐PD was 5 years younger in the North African (hazard ratio [HR] = 1.48, 95% confidence interval [CI] = 1.18–1.86, p = 7.0 × 10 −4 ) compared with the European ancestry group. In contrast, the median AAO was 5 years older in the Ashkenazi Jewish (HR = 0.61, 95% CI = 0.50–0.75, p = 4.0 × 10 −6 ) compared with the European ancestry group. Additionally, patients from Israel (HR = 1.59, 95% CI = 1.30–1.39, p = 4.0 × 10 −6 ) and Tunisia (HR = 2.57, 95% CI: 2.16–3.06, P < 2.0 × 10 −16 ) had a median 5‐year and 10‐year younger AAO compared with patients from the United States, respectively. Last, when focusing only on individuals with an Ashkenazi Jewish background, patients from Israel still had a younger AAO than those from the United States (HR = 1.82, 95% CI = 1.48–2.24, p = 1.5 × 10 −8 ). Analogously, assessing only patients from the United States, the Ashkenazi Jewish ancestry group still had an older AAO than the European ancestry group (HR = 0.51, 95% CI = 0.39–0.67, p = 1.3 × 10 −6 ). Interpretation: Our results provide evidence that a person's genetic ancestry and country of origin are associated with the AAO of LRRK2 ‐PD. This highlights the potential impact of both genetic and environmental factors on LRRK2 ‐PD AAO. ANN NEUROL 2026;99:1394–1404

4 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAnnica Gosch
Annica Gosch
Sebastian SendelSebastian Sendel
Sebastian Sendel
ACAmke Caliebe
Amke Caliebe
CCCornelius Courts
Cornelius Courts
Background In forensic molecular biology, the main task consists of identifying individuals who contributed to biological traces recovered from (potential) crime scenes. However, to support evidence-based reconstruction of the course of activities having taken place at the scene, contextualising information regarding how and when a biological trace was deposited is oftentimes required. Results Here we present the development of a forensic molecular biological analysis procedure for the prediction of the time-of-day at which a bloodstain has been deposited by targeted quantification of selected mRNA markers. Time-of-day candidate prediction markers with diurnally rhythmic expression have previously been identified by whole transcriptome sequencing. Here, we build on our previous findings by establishing a targeted cDNA sequencing protocol on an Ion S5 massively parallel sequencing device for the targeted gene expression quantification of 74 time-of-day candidate prediction markers. Based on expression measurements of these markers in 408 blood samples (from 51 individuals deposited at eight time points over a day), we establish and compare different statistical methods to predict time of deposition. The most suitable model employing penalised regression achieved a root mean squared error of 3 hours and 44 minutes with 78 % of predictions being correct within +/- 4 h (evaluated by five-fold cross-validation). Conclusions Our study provides the first prediction model for time-of-day of bloodstain deposition based on targeted RNA sequencing and thus represents an important step towards forensic trace deposition timing. It thereby relevantly contributes to the growing knowledge on Transcriptomic Analyses for the Contextualisation of Evidential Stains (TrACES).

4 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
Sebastian SendelSebastian Sendel
Sebastian Sendel
ZLZied Landoulsi
Zied Landoulsi
KLKatja Lohmann
Katja Lohmann
BLBjörn-Hergen Laabs
Björn-Hergen Laabs
MKMeike Kasten
Meike Kasten
ACAmke Caliebe
Amke Caliebe
While genetic causes are identified in up to 15% of all Parkinson’s disease (PD) patients, the remaining idiopathic PD (iPD) patients are attributed to polygenic risk, environmental and lifestyle factors, and interactions thereof. We applied five advanced polygenic score (PGS) tools to data from 1,762 iPD patients and 4,227 healthy controls of European ancestry, resulting in the development of a novel iPD-PGS with significantly improved discriminative performance compared to existing models with an AUC of 0.680 (95% confidence interval (-CI): [0.665, 0.695]). Validation in independent cohorts confirmed its robustness. Notably, patients with early-onset iPD exhibited markedly high PGS values when compared to late-onset iPD patients and healthy controls, underlining the high polygenetic burden in these individuals. We subsequently applied our novel iPD-PGS to carriers of heterozygous PRKN variants and GBA1 coding risk variants. In both cases, our findings suggest that part of the penetrance in these genetic forms of PD can be explained by the same polygenic alterations as observed mitigating iPD. The discriminative potential was greater for GBA1 than for PRKN ( GBA1 : AUC=0.639, 95%-CI=[0.590, 0.687], PRKN : AUC=0.594, 95%-CI=[0.501, 0.687]). Our study highlights the potential of advanced PGSs in PD research, particularly for understanding varying penetrance in genetic PD and identifying high-risk individuals.

17 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
TLTheresa Lüth
Theresa Lüth
CGCarolin Gabbert
Carolin Gabbert
TKTeresa Kleinz
Teresa Kleinz
CMChristoph Much
Christoph Much
BLBöjrn-Hergen Laabs
Böjrn-Hergen Laabs
G(Global Parkinson's Genetics Program (GP2)
Global Parkinson's Genetics Program (GP2)
Background: Reliable biomarkers for Parkinson’s disease (PD) pathology detection are essential for research. The α-synuclein (aSyn) seed amplification assay (SAA) is a validated biomarker for misfolded aSyn. Objectives: To assess the association between aSyn SAA and LRRK2 -related PD ( LRRK2 -PD) and its link to mitochondrial genetic burden. Methods: We included N=76 LRRK2 p.Gly2019Ser variant carriers (N=22 affected, N=54 unaffected), N=714 patients with idiopathic PD (iPD), and N=411 controls from Norway. We analyzed cerebrospinal fluid (CSF)-based aSyn SAA in N=10 PD patients and N=30 unaffected LRRK2 p.Gly2019Ser carriers, alongside N=6 controls and N=56 iPD patients. A mitochondrial polygenic score (MGS) was derived from genotyping data, using PPMI as an additional cohort (iPD: N=355, LRRK2 -PD: N=118). Results: Seeding was observed in 80%of patients with LRRK2 -PD, and in one unaffected variant carrier (AUC=0.97, CI 0.92-1.00). In a meta-analysis across two PD cohorts, higher MGS was associated with increased aSyn seeding (pooled β=0.38, p=0.028). Conclusions: CSF-based aSyn SAA can discriminate between LRRK2 -PD and unaffected carriers. Our findings support an association with mitochondrial burden and aSyn seeding.

28 September 2026 in Movement Disorders
Verified
Journal Article
Open access
PDF file
TLTheresa Lüth
Theresa Lüth
CGCarolin Gabbert
Carolin Gabbert
TKTeresa Kleinz
Teresa Kleinz
CMChristoph Much
Christoph Much
BLBjörn-Hergen Laabs
Björn-Hergen Laabs
G(Global Parkinson's Genetics Program (GP2)
Global Parkinson's Genetics Program (GP2)
Background: Reliable biomarkers for Parkinson's disease (PD) pathology detection are essential for research. α‐Synuclein (aSyn) seed amplification assay (SAA) is a validated biomarker for misfolded aSyn. Objective: The aim was to assess the association between aSyn SAA and LRRK2 ‐related PD ( LRRK2 ‐PD) and its link to mitochondrial genetic burden. Methods: We included N = 76 LRRK2 p.Gly2019Ser variant carriers (N = 22 affected, N = 54 unaffected), N = 714 patients with idiopathic PD (iPD), and N = 411 controls from Norway. We analyzed cerebrospinal fluid (CSF)–based aSyn SAA in N = 10 PD patients and N = 30 unaffected LRRK2 p.Gly2019Ser carriers, alongside N = 6 controls and N = 56 iPD patients. A mitochondrial polygenic score (MGS) was derived from genotyping data, using Parkinson's Progression Markers Initiative (PPMI) as an additional cohort (iPD: N = 355, LRRK2 ‐PD: N = 118). In patients with PD, we explored the association between mitochondrial genetic burden and aSyn SAA outcome as well as SAA kinetic measurements. Results: Seeding was observed in 80% of patients with LRRK2 ‐PD and in 1 unaffected variant carrier (AUC = 0.97, confidence interval [CI] 0.92–1.00). In an exploratory meta‐analysis across 2 PD cohorts, higher MGS was associated with increased aSyn seeding (pooled β = 0.43, odds ratio [OR] = 1.54, P = 0.014). In the Norwegian cohort, assessing aSyn SAA kinetic measurements, higher MGS was associated with a higher maximum slope (β = 1.22, standard error [SE] = 0.50, P = 0.020). In PPMI, higher MGS was associated with shorter time to threshold (β = −0.34, SE = 0.13, P = 0.007) and time to maximum slope (β = −0.35, SE = 0.13, P = 0.007). Conclusions: CSF‐based aSyn SAA can discriminate between LRRK2 ‐PD and unaffected carriers. Our findings suggest an association between mitochondrial genetic burden and aSyn seeding. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.